SCVC

Zero Point Motion develops inertial sensing technology for precise positioning and navigation, combining cavity optomechanics with a hybrid micro-electro-mechanical system and photonic integrated circuit technology to deliver ultra-low-noise readouts of acceleration and rotation; its sensors include ultra-sensitive accelerometers and gyroscopes built on silicon photonics, enabling high-accuracy motion sensing for demanding applications, including defense, agritech, and autonomous vehicles.

Theo Ai develops an AI-based platform that predicts outcomes of legal disputes. It uses predictive analytics to estimate odds of success and recovery ranges, supporting the legal community in data-driven decision-making.

Nebu-Flow is a manufacturer focused on the development of advanced inhaled drugs aimed at patients with respiratory disorders. The company specializes in innovative pulmonary drug-delivery technology that allows for efficient administration of difficult-to-nebulize medications directly to the lungs. This includes existing formulations as well as emerging therapeutics such as biologics, nanomedicines, and vaccines. Nebu-Flow's technology is designed to control droplet size for optimal deep lung deposition, facilitating injection-free systemic drug delivery through inhalation. The company is dedicated to minimizing its environmental impact while ensuring the creation of a user-friendly and high-performing nebulizer for effective treatment of respiratory diseases.

IsomAb is a biotechnology company focused on the evaluation and development of isoform-specific antibodies aimed at treating diseases, particularly peripheral arterial disease. The company's innovative platform targets altered isoforms of pathogenic messenger ribonucleic acid and vascular endothelial growth factor A, which are implicated in various ischemic conditions. By addressing these specific isoforms, IsomAb aims to enhance blood flow and prevent collateral formation in affected patients. This approach provides new therapeutic options for diseases that currently have limited treatment alternatives, potentially improving outcomes for individuals suffering from these conditions.

Delta g specializes in developing advanced underground imaging systems using quantum technology. It spun out from the University of Birmingham.

Scarlet Therapeutics is focused on creating innovative red blood cell-based therapeutics through its proprietary platform for generating therapeutic red blood cells (tRBCs). These tRBCs are designed to carry additional proteins that deliver therapeutic benefits, allowing for broad application across various medical conditions. The company aims to address a range of diseases, including hyperammonemia, hyperoxaluria, metabolic disorders, cancer, and autoimmune diseases. By utilizing cell lines for therapeutic generation rather than relying on donated stem cells, Scarlet Therapeutics seeks to enhance the efficacy of treatments in the healthcare sector, potentially transforming the approach to disease management.

Carbometrics is a specialist chemistry company focused on the design, synthesis and derivatisation of highly selective carbohydrate-binding molecules. Its technology centers on glucose-binding receptors developed for sensing applications, produced through a scalable synthesis that delivers robustness under demanding conditions. Building on more than 20 years of research from Professor Anthony Davis’s group at the University of Bristol, the company aims to realise a reliable glucose sensing platform for healthcare use, including continuous glucose monitoring. The approach seeks to enable accurate, robust detection of glucose in diverse environments, supporting the development of next-generation glucose sensors.

VyperCore is a technology company that specializes in the development of modified RISC-V processors aimed at enhancing the performance and security of compute-intensive workloads. By focusing on memory safety, VyperCore's innovative processor technology addresses vulnerabilities commonly associated with traditional computing systems. The company also provides memory allocation management solutions that facilitate the deployment of accelerator cards in data centers, optimizing application software for a diverse range of general-purpose programming languages. Through these advancements, VyperCore seeks to transform the landscape of modern software applications by improving both their efficiency and security.

Forefront RF is a semiconductor company specializing in radio frequency technology. Its core product enables simpler designs for multi-band smartphones, wearables, and IoT devices, enhancing global accessibility and signal reception.

Kelpi is a sustainable biotech startup and material innovation company that uses seaweed to bio-refine a biodegradable bioplastic coating for paper and card packaging. The coating provides a renewable alternative to fossil-fuel plastics used in packaging for food, beverages, cosmetics and personal care, and is designed to be recyclable, biodegradable and home-compostable in suitable environments. By enabling a thin seaweed-based biomaterial to coat paper and card, Kelpi aims to eliminate single-use plastics while delivering marine-safe packaging.

IsomAb is a biotechnology company focused on the evaluation and development of isoform-specific antibodies aimed at treating diseases, particularly peripheral arterial disease. The company's innovative platform targets altered isoforms of pathogenic messenger ribonucleic acid and vascular endothelial growth factor A, which are implicated in various ischemic conditions. By addressing these specific isoforms, IsomAb aims to enhance blood flow and prevent collateral formation in affected patients. This approach provides new therapeutic options for diseases that currently have limited treatment alternatives, potentially improving outcomes for individuals suffering from these conditions.

Open Bionics develops advanced bionic limbs for individuals with upper limb differences. It specializes in the Hero Arm, a lightweight, ventilated multi-grip bionic arm featuring adjustable sockets and aesthetic covers. The company offers custom-fitted designs using 3D printing technology, aiming to make cutting-edge bionic solutions more accessible.

Nebu-Flow is a manufacturer focused on the development of advanced inhaled drugs aimed at patients with respiratory disorders. The company specializes in innovative pulmonary drug-delivery technology that allows for efficient administration of difficult-to-nebulize medications directly to the lungs. This includes existing formulations as well as emerging therapeutics such as biologics, nanomedicines, and vaccines. Nebu-Flow's technology is designed to control droplet size for optimal deep lung deposition, facilitating injection-free systemic drug delivery through inhalation. The company is dedicated to minimizing its environmental impact while ensuring the creation of a user-friendly and high-performing nebulizer for effective treatment of respiratory diseases.

OxDX is a spinout that combines the power of single-molecule fluorescent microscopy with machine learning to identify pathogens in under a minute. They use a universal labelling system to light up everything in our sample, image the sample using super-resolution fluorescence microscopy, and analyse the images in our neural network.

Imophoron is a biotechnology company focused on developing a next-generation rapid-response vaccine platform known as ADDomer. This innovative platform is designed to address infectious diseases and potential outbreaks by utilizing a self-assembling thermotolerant protein. This technology allows for the rapid insertion of a large number of peptide and protein epitopes into a single particle, making it well-suited for the creation of next-generation vaccines. By enabling more efficient vaccine development, Imophoron aims to enhance accessibility for patients and healthcare providers in the fight against major diseases.

Forefront RF is a semiconductor company specializing in radio frequency technology. Its core product enables simpler designs for multi-band smartphones, wearables, and IoT devices, enhancing global accessibility and signal reception.

Carbometrics is a specialist chemistry company focused on the design, synthesis and derivatisation of highly selective carbohydrate-binding molecules. Its technology centers on glucose-binding receptors developed for sensing applications, produced through a scalable synthesis that delivers robustness under demanding conditions. Building on more than 20 years of research from Professor Anthony Davis’s group at the University of Bristol, the company aims to realise a reliable glucose sensing platform for healthcare use, including continuous glucose monitoring. The approach seeks to enable accurate, robust detection of glucose in diverse environments, supporting the development of next-generation glucose sensors.

Cytoseek Limited is a biotechnology company based in Bristol, United Kingdom, that specializes in developing innovative cell therapies aimed at treating cancer, heart disease, osteoarthritis, and diabetic wound healing. Founded in 2017 as a spinout from the University of Bristol, Cytoseek focuses on cell membrane augmentation technology, which enhances the functionality of cell therapies by enabling tissue-specific targeting and improving cell survivability. The company is currently conducting proof of principle studies to validate the efficacy of its technologies and is actively seeking partnerships with other cell therapy organizations to advance its products towards clinical application, with the overarching goal of improving human health.